Cyclodextrin-Derived Intrinsically Bioactive Nanoparticles for Treatment of Acute and Chronic Inflammatory Diseases

© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 31(2019), 46 vom: 20. Nov., Seite e1904607
1. Verfasser: Guo, Jiawei (VerfasserIn)
Weitere Verfasser: Li, Dandan, Tao, Hui, Li, Gang, Liu, Renfeng, Dou, Yin, Jin, Taotao, Li, Lanlan, Huang, Jun, Hu, Houyuan, Zhang, Jianxiang
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article bioactive nanoparticles cyclodextrin inflammation macrophages neutrophils Anti-Inflammatory Agents beta-Cyclodextrins betadex JV039JZZ3A
LEADER 01000caa a22002652c 4500
001 NLM301910049
003 DE-627
005 20250226023425.0
007 cr uuu---uuuuu
008 231225s2019 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.201904607  |2 doi 
028 5 2 |a pubmed25n1006.xml 
035 |a (DE-627)NLM301910049 
035 |a (NLM)31583783 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Guo, Jiawei  |e verfasserin  |4 aut 
245 1 0 |a Cyclodextrin-Derived Intrinsically Bioactive Nanoparticles for Treatment of Acute and Chronic Inflammatory Diseases 
264 1 |c 2019 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 30.03.2020 
500 |a Date Revised 30.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
520 |a Inflammation is a common cause of many acute and chronic inflammatory diseases. A major limitation of existing anti-inflammatory therapeutics is that they cannot simultaneously regulate pro-inflammatory cytokine production, oxidative stress, and recruitment of neutrophils and macrophages. To overcome this limitation, nanoparticles (NPs) with multiple pharmacological activities are synthesized, using a chemically modified cyclic oligosaccharide. The manufacture of this type of bioactive, saccharide material-based NPs (defined as LCD NP) is straightforward, cost-effective, and scalable. Functionally, LCD NP effectively inhibits inflammatory response, oxidative stress, and cell migration for both neutrophils and macrophages, two major players of inflammation. Therapeutically, LCD NP shows desirable efficacies for the treatment of acute and chronic inflammatory diseases in mouse models of peritonitis, acute lung injury, and atherosclerosis. Mechanistically, the therapeutic benefits of LCD NP are achieved by inhibiting neutrophil-mediated inflammatory macrophage recruitment and by preventing subsequent pro-inflammatory events. In addition, LCD NP shows good safety profile in a mouse model. Thus, LCD NP can serve as an effective anti-inflammatory nanotherapy for the treatment of inflammatory diseases mainly associated with neutrophil and macrophage infiltration 
650 4 |a Journal Article 
650 4 |a bioactive nanoparticles 
650 4 |a cyclodextrin 
650 4 |a inflammation 
650 4 |a macrophages 
650 4 |a neutrophils 
650 7 |a Anti-Inflammatory Agents  |2 NLM 
650 7 |a beta-Cyclodextrins  |2 NLM 
650 7 |a betadex  |2 NLM 
650 7 |a JV039JZZ3A  |2 NLM 
700 1 |a Li, Dandan  |e verfasserin  |4 aut 
700 1 |a Tao, Hui  |e verfasserin  |4 aut 
700 1 |a Li, Gang  |e verfasserin  |4 aut 
700 1 |a Liu, Renfeng  |e verfasserin  |4 aut 
700 1 |a Dou, Yin  |e verfasserin  |4 aut 
700 1 |a Jin, Taotao  |e verfasserin  |4 aut 
700 1 |a Li, Lanlan  |e verfasserin  |4 aut 
700 1 |a Huang, Jun  |e verfasserin  |4 aut 
700 1 |a Hu, Houyuan  |e verfasserin  |4 aut 
700 1 |a Zhang, Jianxiang  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 31(2019), 46 vom: 20. Nov., Seite e1904607  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnas 
773 1 8 |g volume:31  |g year:2019  |g number:46  |g day:20  |g month:11  |g pages:e1904607 
856 4 0 |u http://dx.doi.org/10.1002/adma.201904607  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 31  |j 2019  |e 46  |b 20  |c 11  |h e1904607